Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 16/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648255 | 0.88 | TNK2 (0.54) | IGF1RPDPK1ABL1EGFRRAF1 | |
| SCHEMBL8404244 | 0.87 | IGF1R (0.45) | IGF1RPDPK1ABL1EGFRRAF1 | |
| SCHEMBL13629011 | 0.86 | TNK2 (0.55) | IGF1RPDPK1ABL1EGFRRAF1 | |
| SCHEMBL8402327 | 0.86 | FGFR2 (0.52) | IGF1RTNK2FGFR2 | |
| SCHEMBL8402085 | 0.85 | TNK2 (0.50) | IGF1RPDPK1ABL1EGFRRAF1 | |
| SCHEMBL10242104 | 0.84 | TNK2 (0.42) | RAF1SRCTNK2FGFR2 | |
| SCHEMBL8399665 | 0.82 | TNK2 (0.63) | IGF1RPDPK1ABL1EGFRRAF1 | |
| SCHEMBL10242615 | 0.82 | TNK2 (0.52) | TNK2FGFR2 | |
| SCHEMBL12648311 | 0.82 | IGF1R (0.48) | IGF1RPDPK1ABL1EGFRRAF1 | |
| SCHEMBL13629425 | 0.81 | TNK2 (0.47) | IGF1RTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943767-B2 | Fused bicyclic mTOR inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | IGF1R 1033/4885PDPK1 72/4885ABL1 430/4885 |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | IGF1R 1033/4885PDPK1 72/4885ABL1 430/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | IGF1R 67/4885PDPK1 9/4885ABL1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.